SRP-4045

DRUG3 trials

Sponsors

Sarepta Therapeutics, Inc.

Conditions

Duchenne Muscular DystrophyDuchenne muscular dystrophy

Phase 1

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

CompletedNCT02530905

Sarepta Therapeutics, Inc.Duchenne Muscular Dystrophy

Start: 2015-10-08End: 2018-10-03Updated: 2021-05-17

Phase 3

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

CompletedNCT02500381

Sarepta Therapeutics, Inc.Duchenne Muscular Dystrophy

Start: 2016-09-28End: 2025-10-16Updated: 2025-11-18

A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc.Duchenne muscular dystrophy

Target: 4Updated: 2024-02-28

Related Papers

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial

Nucleic Acid Therapeutics2021-11-17114 citations